DifGen Pharmaceuticals launches generic Suboxone

DifGen has launched its first complex oral sublingual/buccal film—a generic to Suboxone (Buprenoprhine/Naloxone) in the U.S. market.

DifGen also has successfully completed an FDA audit of its manufacturing site in Florida, Aveva Drug Delivery systems—the first audit after it's acquisition of this facility in April, 2023.

[Read more: FDA clears Dr. Reddy’s generic Suboxone sublingual film]

In a joint statement, Ramandeep Singh Jaj and Santhanakrishnan Srinivasan, founders and co-CEOs of DifGen said, "This is a truly remarkable achievement. Two important milestones within just four months of our first ever acquisition and foray into the US manufacturing and marketing space. It was a herculean effort and kudos to our entire team that made this dream a reality. DifGen is committed in establishing and expanding its local US manufacturing base which will provide patients affordable lifesaving medication with highest quality and consistent supply."

[Read more: Dr. Reddy's relaunches generic Suboxone sublingual film]